Chemoprevention of human cancer: Biology and therapy

Critical Reviews in Oncology/Hematology

Volumn 25, Issue 3, 1997, Pages 139-174

  Tanaka, Takuji ^a  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 INDOLEMETHANOL; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; BIOLOGICAL MARKER; CANTHAXANTHIN; CHLOROGENIC ACID; CURCUMIN; ELLAGIC ACID; FENRETINIDE; GENISTEIN; ISOTRETINOIN; LIMONENE; MOLYBDENUM; NICOTINIC ACID; POLYPRENOIC ACID; PROTEIN P53; QUERCETIN; RETINOIC ACID; RETINOID; RETINOL; RIBOFLAVIN; SARCOPHYTOL A; SELENIUM; TAMOXIFEN; UNINDEXED DRUG; ZINC;

APOPTOSIS; CANCER PREVENTION; CARCINOGENESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DOUBLE BLIND PROCEDURE; ENDOMETRIUM HYPERPLASIA; GENE THERAPY; HETEROZYGOSITY LOSS; HUMAN; HYPERLIPIDEMIA; LIVER CARCINOMA; LUNG CARCINOMA; OCCUPATIONAL EXPOSURE; ONCOGENE; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRECANCER; PROSTATE CARCINOMA; RANDOMIZED CONTROLLED TRIAL; REVIEW; SKIN CARCINOMA; TUMOR SUPPRESSOR GENE; XEROSTOMIA;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CLINICAL TRIALS; HUMANS; NEOPLASMS;

EID: 0030959572     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(97)00232-1     Document Type: Review

References (377)

1. Magrath I, Litvak J. Cancer in developing countries: opportunity and challenge. J Natl Cancer Inst 85:862-874, 1993.
2. Meyskens FLJ. Coming of age - the chemoprevention of cancer. N Engl J Med 323:825-827, 1990.
3. Monfardini S, Yancik R. Commentary. Cancer in the elderly: meeting the challenge of an aging population. J Natl Cancer Inst 85:532-538, 1993.
4. Kobayashi Y, Arimoto H, Watanabe S. Occurrence of multiple primary cancer from 1962 to 1989. Jpn J Clin Oncol 21:233-251, 1991.
5. The Health Consequences of Smoking: Cancer. Department of Health and Tumour Services (DHS) 82-50179. Washington DC: Public Health Service, 1982.
6. Sugimura T, Terada M, Yokota J, Hirohashi S, Wakabayashi K. Multiple genetic alterations in human carcinogenesis. Environ Health Perspect 98:5-12, 1992.
7. Anderson MW, Reynolds SH, You M, Maronpot BM. Role of protooncogene activation in carcinogenesis. Environ Health Perspect 98:13-24, 1992.
8. Evans IU, Prosser J. Tumor-suppressor genes: cardinal factors in inherited predisposition to human cancers. Environ Health Perspect 98:25-37, 1992.
9. Barrett JC. Mechanisms of multistep carcinogenesis and carcinogen risk assessment. Environ Health Perspect 100:9-20, 1993.
10. Loeb IA. Molecular oncology into the twenty-first century-presidential address. Cancer Res 49:5489-5496, 1989.
11. Renan MJ. How many mutations are required for tumorigenesis? Implications from human cancer data. Mol Carcinogenesis 7:139-146, 1993.
12. Sporn MB, Newton DL. Chemoprevention of cancer with retinoids. Fed Proc 38:2528-2534, 1979.
13. Doll R. Strategy for detection of cancer hazards to man. Nature 265:589-596, 1977.
14. Higginson J, Muir CS. Environmental carcinogenesis: Misconceptions and limitations to cancer control. J Natl Cancer Inst 63:1291-1298, 1979.
15. Knudson AGJ. Genetic predisposition to cancer. In: Hiatt HH, Watson JD, Winston JA, eds. Origin of Human Cancer, Book A. New York: Cold Spring Harbor, 1977: 45-52.
16. Doll R, Peto R. The causes of cancer: quantitative estimate of avoidable risks of cancer in the United States today. J Natl Cancer Inst 66:1191-1308, 1981.
17. Walirendorf J, Chang-Claude J, Liang QS, Rei YG, Munoz N, Crespi M, Raedsch R, Thurnham D, Correa P. Precursor lesions of oesophageal cancer in young people in a high-risk population in China. Lancet 11:1239-1241, 1989.
18. Kono S, Ikeda M, Tokudome S, Kuratsune M. A case-control study of gastric cancer and diet in Northern Kyusyu, Japan. Jpn J Cancer Res 79:1067-1074, 1988.
19. Correa P. Precursors of gastric and esophageal cancer. Cancer 50:1554-2565, 1982.
20. Weinberg RA. Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res 49:3713-3721, 1989.
21. Tanaka T. Cancer chemoprevention. Cancer J 5:11-16, 1992.
22. Tanaka T. Cancer chemoprevention by natural products (Review). Oncol Rep 1:1139-1155, 1994.
23. Tanaka T. Chemoprevention of oral carcinogenesis. Oral Oncol Eur J Cancer 31B:3-15, 1995.
24. Boone CW, Kelloff GJ, Steele VE. Natural history of intraepithelial neoplasia in humans with implications for cancer chemoprevention strategy. Cancer Res 52:1651-1659, 1992.
25. Wattenberg LW. Chemoprevention of cancer. Cancer Res 45:1-8, 1985.
26. Boone CW, Kelloff GJ, Malone WE. Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: a review. Cancer Res 50:2-9, 1990.
27. Ip C. Feasibility of using lower doses of chemopreventive agents in a combination regimen for cancer protection. Cancer Lett 39:239-246, 1988.
28. Ip C, Ganther HE. Combination of blocking agents and suppressing agents in cancer. Carcinogenesis 12:365-367, 1991.
29. Reddy BS, Nayini J, Tokumo K, Rigotty J, Zang E, Kelloff G. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug, with D,L-α-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res 50:2562-2568, 1990.
30. Blot WJ, Li J-Y, Taylor PR, Guo W, Dawsey S, Wang G-Q, Yang CS, Zheng S-F, Gail M, Li Y, Yu Y, Liu B, Tangrea J, Su Y, Liu F, Fraumeri JF Jr, Zimang Y-H, Li B. Nutrition intervention trials in Linxian, China: Supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 85:1483-1492, 1993.
31. Li J-Y, Taylor PR, Li B, Dawsey S, Wang G-Q, Ershow AG, Guo W, Liu S-F, Yang CS, Shen Q, Wang W, Mark SD, Zou X-N, Greenwald P, Nu Y-P, Blot WJ. Nutrition intervention trials in Linxian, china: Multiple vitamin/mineral supplementation, cancer incidence, and disease-specific mortality among adults with esophageal dysplasia. J Natl Cancer Inst 85:1492-1498, 1993.
32. Sporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical carcinogenesis by vitamin A and the synthetic analogs (retinoids). Fed Proc 35:1332-1338, 1976.
33. Pitot HC. Progression: the terminal stage in carcinogenesis. Jpn J Cancer Res 80:599-607, 1989.
34. Rous P, Kidd JG. Conditional neoplasms and sub-threshold neoplastic state: a study of the tar tumors of rabbits. J Exp Med 73:369-390, 1941.
35. Morttram JC. A developing factor in experimental blastogenesis. Pathol Bacteriol 56:181-187, 1944.
36. Berenblum I, Shubik P. A new quantitative approach to the study of stages of chemical carcinogenesis in the mouse's skin. Br J Cancer 1:383-391, 1947.
37. Foulds L. The experimental study of tumor progression: a review. Cancer Res 14:327-339, 1954.
38. Slaga TJ, Butler Ap. Cellular and biochemical changes during multistage skin tumor promotion. Int Symp Princess Takamatsu Cancer Res Fund 14:293-301, 1983.
39. Armitage P, Doll R. The age distribution of cancer and a multistage theory of carcinogenesis. Br J Cancer 8:1-12, 1954.
40. Okamoto T, Ohno Y, Tsugane S, Watanabe S, Shimoyama M, Tajima K, Miwa M, Shimosato K. Multi-step carcinogenesis model for adult T-cell leukemia. Jpn J Cancer Res 80:191-195, 1989.
41. Farber F, Cameron R. The sequential analysis of cancer development. Adv Cancer Res 31:125-226, 1980.
42. Hecker F, Fusenig NE, Kunz W, Marks F, eds. Carcinogenesis - A Comprehensive Survey, Vol. 7. New York: Raven Press, 1982.
43. Farber E, Sarma DSR. Hepatocarcinogenesis: a dynamic cellular perspective. Lab Invest 56: 4-22, 1987.
44. Clayson DB. The need for biological risk assessment in reaching decisions about carcinogens. Mutat Res 185:243-289, 1987.
45. Preston-Martin S, Pike MC, Ross RK, Jones PA. Increased cell division as a cause of human cancer. Cancer Res 50:7415-7421, 1990.
46. Melnick RI, Huff J, Barrett JC, Maronpot RR, Lucier G, C.J.P. Cell proliferation and chemical carcinogenesis: a symposium overview. Mol Carcinogenesis 7:135-138, 1993.
47. Columbarno A, Rajalakshmi S, Sarma DSR. Requirement of cell proliferation for the initiation of liver carcinogenesis as assayed by three different procedures. Cancer Res 41:2079-2083, 1981.
48. Stott WT, Reitz RH, Schumann AM, Watanabe PG. Genetic and nongenetic events in neoplasia. Fd Cosmet Toxicol 19:567-576, 1981.
49. Land H, Prada LF, Weinberg R. Cellular oncogenes and multistep carcinogenesis. Science 222:771-778, 1983.
50. Coni P, Bigone FA, Pichiri G, Ledda-Columbano GM, Columbano A, Rao PM, Rajalakshmi S, Sarma DS. Studies on the kinetics of expression of cell cycle dependent proto-oncogenes during mitogen-induced liver cell proliferation. Cancer Lett 47:115-119, 1989.
51. Braun L, Mead JE, Panzica M, Mikumo R, Bell GI, Fausto N. Transforming growth factor β-mRNA increases during liver regeneration: a possible paracrine mechanism of growth regulation. Proc Nati Acad Sci USA 85:1539-1543, 1988.
52. Mead JE, Fausto N. Transforming growth factor a may be a physiological regulator of liver regeneration by means of an autocrine mechanism. Proc Natl Acad Sci USA 86:1558-1562, 1989.
53. Butterworth BE, Slaga TJ, Farland W, McClain M, eds. Chemically Induced Cell Proliferation: Implications for Risk Assessment. New York: Wiley-Liss, 1991; 1-547.
54. Pitot HC, ed. Fundamentals of Oncology, 3rd edn. New York: Marcel Dekker, 1986.
55. Pitot HC, Sirica AE. The stages of initiation and promotion in hepatic carcinogenesis. Biochim Biophys Acta 605:191-215, 1980.
56. Williams GT. Programmed cell death: apoptosis and oncogenesis. Cell 65:1097-1098, 1991.
57. Sasaki M, Yoshida MC, Kagami K, Takeuci N, Kobayashi H, Dempo K, Mori M. Spontaneous hepatitis in an inbred strain of Long-Evans rats. Rat News Lett 14:4-6, 1985.
58. Masuda R, Yoshida MC, Sasaki M, Dempo K, Mori M. Hereditary hepatitis in LEC rats is controlled by a single autosomal recessive gene. Lab Anim 22:166-169, 1988.
59. Li Y, Togashi Y, Sato S, Emoto T, Kang JH, Takeichi N, Kobayashi H, Kojima Y, Une Y, Uchino J. Spontaneous accumulation of copper in LEC rats with hereditary hepatitis: a model of Wilson's disease. J Clin Invest 87:1858-1861, 1991.
60. Sone H, Maeda M, Gotoh M. Genetic linkage between copper accumulation and hepatilis/hepatoma development in LEC rats. Mol Carcinogenesis 5:199-204, 1992.
61. Oyamada M, Dempo K, Fujimoto Y, Takahashi H, Satoh MI, Mori M, Masuda R, Yoshida MC, Satoh K, Sato K, Nagao M. Spontaneous occurrence of placental glutathione S-transferase-positive foci in the livers of LEC rats. Jpn J Cancer Res 79:5-8, 1988.
62. Sawaki M, Enomot K, Takahashi H, Nakajima Y, Mori M. Phenotype of preneoplastic and neoplastic liver lesions during Spontaneous liver carcinogenesis of LEC rats. Carcinogenesis 11:1857-1861, 1990.
63. Takahashi H, Enomoto K, Nakajima Y, Mon M. High sensitivity of the LEC rat liver to the carcinogenic effect of diethylnitrosamine. Cancer Lett 51:247-250, 1990.
64. Schulte-Hermann R, Bursch W, Parzefall W. Mitogenesis and programmed cell death as determinants of carcinogenicity of nongenotoxic compounds. In: Butterworth BE, Slaga TJ, Farland W, McClain M, eds. Chemically Induced Cell proliferation: Implications for Risk Assessment. New York: Wiley-Liss, 1991; 237-244.
65. Bishop JM. Molecular themes in oncogenesis. Cell 64:235-248, 1991.
66. Hunter T. Cooperation between oncogenes. Cell 64:249-270, 1991.
67. Cantley LC, Auger KR, Carpenter C, Duckworth B, Graziani A, Kapeller R, Soltoff S. Oncogenes and transduction. Cell 64:281-302, 1991.
68. Cross M, Dexter TM. Growth factors in development, transformation, and tumorigenesis. Cell 64:271-280, 1991.
69. Lewin B. Oncogenic conversion by regulatory changes in transcription factors. Cell 64:303-312, 1991.
70. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334-335, 1990.
71. Harris CC. p53 tumor suppressor gene involvement in human carcinogenesis. Symposium on Cell Proliferation and Chemical Carcinogenesis. Research Triangle Park, NC, 1992.
72. Preston-Martin S, Pike MC, Ross RK, Henderson BE. Epidemiologic evidence for the increased cell proliferation model of carcinogenesis. Environ Health Perspect 101(Suppl 5):137-138, 1993.
73. Boveri T. Zur Frage der Entstehung maligner Tumoren. Jena: Verlag von Gustav Fischer, 1914.
74. Boveri T. The Origin of Malignant Tumors. Baltimore: Williams and Wilkins, 1929.
75. Bauer KH. Mutationstheorie der Geschwulst-Enstenung, Ubergang von Korperzellen in Geschwulst-Zellen durch Gen-Anderung. Berlin: Springer-Verlag, 1928.
76. Tabin CJ, Bradley SM, Bargmann CI, Weinber RA, Papageorge AG, Scolnick EM, Dhar R, Lowy DR, Chang EH. Mechanism of activation of human oncogene. Nature 300:143-149, 1982.
77. Knudson AG. Genetics of human cancer. Annu Rev Genet 20:231-251, 1986.
78. Nowell P. The clonal evolution of tumor cell populations. Science 194:23-28, 1976.
79. Fearon ER, Cho KR, Nigro JM, Kern SE, Simons JW, Ruppert JM, Hamilton SR, Preisinger AC, Thomas G, Kinzier KW, Vogelstein B. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 247:49-56, 1990.
80. Stanbridge EJ. Identifying tumor suppressor genes in human colorectal cancer. Science 247:12-13, 1990.
81. Sidranski D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B. Clonal expansion of p53 mutant cells is associated with brain tumor progression. Nature 355:846-847, 1992.
82. Bishop JM. The molecular genetics of cancer. Science 235:303-311, 1987.
83. Anderson MW, Reynold SH. Activation of oncogenes by chemical carcinogens. In: Sirica A, ed. The Pathophysiology of Neoplasia. New York: Plenum Press, 1989; 291-304.
84. Klein-Szanto AJP, Anderson MW, Barrett JC, Slaga TJ, eds. Comparative Molecular Carcinogenesis. Prog Clin Biol Res, Vol. 376. New York: Wiley-Liss, 1992; 1-385.
85. Bishop JM. Viral oncogenes. Cell 42:23-38, 1985.
86. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 253:49-53, 1991.
87. Marshall CJ. Tumor suppressor genes. Cell 64:313-326, 1991.
88. Hansen MF, Cavenee WK. Tumor suppressors: recessive mutations that lead to cancer. Cell 53:172-173, 1988.
89. Scrable HJ, Sapienza C, Cavenee WK. Genetic and epigenetic losses of heterozygosity in cancer predisposition and progression. Adv Cancer Res 54:25-62, 1990.
90. Cavenee WK, Dryja TP, Phillips RA, Benedict WF, Godbout R, Gallie BL, Murphree A, Strong LC, White RL. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 305:779-784, 1983.
91. Salki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 239:487-491, 1988.
92. Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5:874-879, 1989.
93. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AMM, Bos JL. Genetic alterations during colorectal-tumor development. N Engl J Med 319:525-532, 1988.
94. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61:759-767, 1990.
95. Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ, Vogelstein B. Prevalence of ras gene mutations in human colorectal cancers. Nature 327:293-297, 1987.
96. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup M, van Tuinen P, Ledbetter DH, Barker DF, Nakamura Y, White R, Vogelstein B. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244:217-221, 1989.
97. Hirohashi S, Sugimura T. Genetic alterations in human gastric cancer. Cancer Cells 3:49-52, 1991.
98. Tahara E. Growth factors and oncogenes in human gastrointestinal carcinomas. J. Cancer Res. Clin Oncol 116:121-131, 1990.
99. Tsuda H, Zhang W, Shimosato Y, Yokota J, Terada M, Sugimura T, Miyamura T, Hirohashi S. Allele loss on chromosome 16 associated with progression of human hepatocellular carcinoma. Proc Natl Acad Sci USA 87:6791-6794, 1990.
100. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 49:4682-4689, 1989.
101. Barrett JC, Wiseman RW. Molecular carcinogenesis in human and rodents. In: Klein-Szanto AJP, Anderson MW, Barrett JC, Slaga TJ, eds. Comparative Molecular Carcinogenesis. Prog Clin Bio Res, Vol. 376. New York: Wiley-Liss, 1992; 1-30.
102. Feron ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61:759-767, 1990:
103. Hunter T. Cooperation between oncogenes. Cell 64:249-270, 1991.
104. Jiang W, Zhang YJ, Kahn SM, Hollstein MC, Santella RM, Lu SH, Harris CC, Montesano R, Weinstein IB. Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc Natl Acad Sci USA 90:9026-9030, 1993.
105. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SY, Stockert E, Day RS III, Johnson BE, Stolnick MH. A cell cycle regulator potentially involved in genesis of many tumor types. Science 436-440, 1994.
106. Xiong Y, Hannon GI, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704, 1993.
107. Li R, Waga S, Hannon GI, Beach D, Stillmann B. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 371:534-537, 1994.
108. Lindahi T.DNA surveillance defect in cancer cells. Curr Biol 4:249-251, 1994.
109. Berenblum I. The modifying influence of dichloroethyl sulphide on the induction of tumours in mice by tar. J Pathol Bacteriol 32:425-434, 1929.
110. Bagheri D, Doeltz MK, Fay JR, Helmes CT, Monasmith LA, Sigman CC. Database of inhibitors of carcinogenesis. Environ Carcinog Revs (J Environ Sci Health) C6:vii-xviii and 262-403, 1989.
111. Saffiotti U, Mantesano R, Sellakumar AR, Borg SA. Experimental cancer of the lung: inhibition by vitamin A of the induction of tracheobronchial squamous metaplasia and squamous cell tumors. Cancer 20:857-864, 1967.
112. Hill DL, Grubbs CJ. Retinoids as chemopreventive and anticancer agents in intact animals. Anticancer Res 2:111-124, 1982.
113. Bollag W, Holdener EE. Retinoids in cancer prevention and therapy. Ann Oncol 3:513-526, 1992.
114. Tallman MS, Wiernik PH. Retinoids in cancer treatment. J Clin Pharmacol 32:868-888, 1992.
115. Mori H, Tanaka T. Chemopreventive retinoids. Drugs Future 18:737-742, 1993.
116. Berenblum I. Cancer prevention as a realizable goal. Cancer 47:2346-2348, 1981.
117. Morse MA, Stoner GD. Cancer chemoprevention: principles and prospects. Carcinogenesis 14:1737-1746, 1993.
118. Bertram B, Frank N. Inhibition of chemical carcinogenesis. Environ Carcinog Ecotoxicol Revs (J Environ Sci Health) C11:1-71, 1993.
119. Fiala ES, Reddy BS, Weisburger JH. Naturally occurring anticarcinogenic substances in food stuffs. Ann Rev Nutr 5:295-321, 1985.
120. De Flora S, Ramel C. Mechanisms of inhibitors of mutagenesis and carcinogenesis. Classification and overview. Mutat Res 202:285-306, 1988.
121. Wattenberg LW. Inhibition of carcinogenesis by minor dietary constituents. Cancer Res 52:2085s-2091s, 1992.
122. Hayatsu H, Arimoto S, Negishi T. Dietary inhibitors of mutagenesis and carcinogenesis. Mutat Res 202:429-446, 1988.
123. Rotstein JB, Slaga TJ. Anticarcinogenesis mechanisms, as evaluated in the multistage mouse skin model. Mutat Res 202:421-427, 1988.
124. Newmark HL. Plant phenolics as inhibitors of mutational and precarcinogenic events. Can J Physiol Pharmacol 65:461-466, 1987.
125. Hocman G. Prevention of cancer: vegetables and plants. Comp Biochem Physiol 936:201-212, 1989.
126. Davis DL. Natural anticarcinogens, carcinogens, and changing patterns in cancer: some speculation. Environ Res 50:322-340, 1989.
127. Nainiki M. Antioxidants/antimutagens in food. CRC Crit Rev Food Sci Nutr 29:273-300, 1990.
128. Ames BN. Dietary carcinogens and anti-carcinogens: oxygen radicals and degenerative disease. Science 221:225-232, 1983.
129. Cassady JM. Natural products as a source of potential cancer chemotherapeutic and chemopreventive agents. J Nat Prod 53:23-41, 1990.
130. Stich HF, Rosin MP. Naturally occurring phenolics as antimutagenic and anticarcinogenic agents. Adv Exp Med Biol 177:1-29, 1984.
131. Stich HF. The beneficial and hazardous effects of simple phenolic compounds. Mutat Res 259:307-324, 1991.
132. Tanaka T, Yoshimi N, Sugie S, Mon H. Protective effects against liver, colon, and tongue carcinogenesis by plant phenols. In: Huang M-T, Ho C-T, Lee CY, eds. Phenolic Compounds in Food and Health II: Antioxidants and Cancer Prevention. Washington, DC: American Chemical Society, 1992; 326-337.
133. Newmark HL. A hypothesis for dietary components as blocking agents of chemical carcinogenesis: plant phenolics and pyrrole pigments. Nutr cancer 6:58-70, 1984.
134. Yang CS, Wang Z-Y. Tea and cancer. J Natl Cancer Inst 85:1038-1049, 1993.
135. Dorgan JF, Schatzkin A. Antioxidant micronutrients in cancer prevention. Hematol/Oncol Clin North Am 5:43-68, 1991.
136. Dragsted LO, Strube M, Larsen JC. Cancer-protective factors in fruits and vegetables: Biochemical and biological background. Pharmacol Toxicol 72:116s-135s, 1993.
137. Hartman PE, Shankel DM. Antimutagens and anticarcinogens: A survey of putative interceptor molecules. Environ Mol Mutag 15:145-182, 1990.
138. Peto R, Doll R, Buckley JD, Sporn MB. Can dietary beta-carotene materially reduce human cancer rates? Nature 290:201-208, 1981.
139. Wattenberg LW. Inhibition of carcinogenesis by minor anutrient constituents of the diet. Proc Nutr Soc 49:173-183, 1990.
140. Thorling EB. Dietary non-nutritive cancer protective factors. Eur J Cancer Prev 2:95-103, 1993.
141. Dorant E, van den Brandt PA, Goldbohm RA, Hermus RJJ, Sturmans F. Garlic and its significance for the prevention of cancer in humans: a critical review. Br J Cancer 67:424-429, 1993.
142. Ito N, Imaida K. Strategy of research for cancer-chemopreven-tion. Teratog Carcinog Mutag 12:79-95, 1992.
143. Block G, Patterson B, Subar A. Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. Nutr Cancer 18:1-29, 1992.
144. Kritchevsky D. Diet, nutrition, and cancer: the role of fiber. Cancer 58:1830-1836, 1986.
145. La Vecchia C, Harlis RE, Wynder EL. Comparative epidemiology of cancer between the United States and Italy. Cancer Res 48:7285-7293, 1988.
146. Colditz GA, Branch LG, Lipnick RJ, Willett WC, Rosner B, Posner BM, Hennekens CH. Increased green and yellow vegetable in take and lowered cancer deaths in an elderly population. Am J Clin Nutr 41:32-36, 1985.
147. Ziegler RG. A review of epidemiologic evidence that carotenoids reduce the risk of cancer. J Nutr 119:116-122, 1989.
148. Fiala ES, Bodotas G, Kulakis C, Wattenberg LW, Weisburger JH. The effects of disulfiram and related compounds on the in vivo metabolism of the colon carcinogen, 1,2-ditnethyihydrazine. Biochem Pharmacol 26:1763-1768, 1977.
149. Wattenberg LW. Inhibition of chemical carcinogenesis. In: Emmelot P, Kriek E, eds. Environmental Carcinogenesis. Amsterdam: North Holland Biomedical Press, 1979; 241-264.
150. Tanaka T, Iwata H, Kanai N, Nishikawa A, Mori H. Inhibitory effect of butylated hydroxytoluene, butylated hydroxyanisole and disulfiram on 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in male ACI rats. J Nutr Growth Cancer 4:239-248, 1987.
151. Hong J-Y, Smith T, Lee M-J, Li W, Ma B-L, Ning SM, Brady JF, Thomas PE, Yang CS. Metabolism of carcinogenic nitrosanilnes by rat nasal mucosa and the effect of diallyl sulfide. Cancer Res 51:1509-1514, 1991.
152. Wargovich MJ. Diallyl sulfide a flavor component of garlic (Allium sativum), inhibits dimethylhydrazine-induced colon cancer. Carcinogenesis 8:487-489, 1987.
153. Sparnins VL, Barany G, Wattenberg LW. Effects of organosulfur compounds from garlic and onions on benzo[a]pyrene-in-duced neoplasia and glutathione S-transferase activity in the mouse. Carcinogenesis 9:131-134, 1988.
154. Wargovich MJ, Woods C, Eng VWS, Stephens LC, Gray K. Chemoprevention of N-nitrosomethylbenzylainine-induced esophageal cancer in rats by the naturally-occurring thioether, diallyl sulfide. Cancer Res 48:6872-6875, 1988.
155. Wargovich MJ. Inhibition of gastrointestinal cancer by organosulfur compounds in garlic. In: Wattenberg L, Lipkin M, Boone CW and Kelloff GJ, eds. Cancer Chemoprevention. Boca Raton, FL: CRC Press, 1992; 195-203.
156. Morse MA, Wang C-X, Stoner GD, Mandai S, Conran PB, Amin SG, Hecht SS, Chung F-L. Inhibition of 4-(methylnitrosainino)-1-(3-pyridyl)-1-butanone-mduced DNA adduct formation and tumorigenicity in the lung of F344 rats by dietary phenethyl isothiocyanate. Cancer Res 49:549-553, 1989.
157. Stoner GD, Morrissey DT, Heur Y-H, Daniel EM, Galati AJ, Wahner SW. Inhibitory effects of phenethyl isothiocyanate on N-nitrosobenzylamine carcinogenesis in the rat esophagus. Cancer Res 51:2063-2068, 1991.
158. Nayini JR, Sugie S, El-Bayoumy K, Rao CV, Rigotty J, Sohn O-S, Reddy BS. Effect of dietary benzylselenocyanate on azoxymethane induced colon carcinogenesis in male F344 rats. Nutr Cancer 15:129-139, 1991.
159. Benson AM, Barretto PB. Effects of disulfiram, diethyldithiocarbamate, bisethylxanthogen and benzyl isothiocyanate on glutathione transferase activities in mouse organs. Cancer Res 45:4219-4223, 1985.
160. Guo Z, Smith TJ, Wang E, Sadrieh N, Ma Q, Thomas PE, Yang CS. Effects of phenethyl isothiocyanate, a carcinogenesis inhibitor, on xenobiotic-metabolizing enzymes and nitrosamine metabolism in rats. Carcinogenesis 13:2205-2210, 1992.
161. Chung F-L. Chemoprevention of lung carcinogenesis by aromatic isothiocyanates. In: Wattenberg L, Lipkin M, Boone CW, Kelloff GJ, eds. Cancer Chemoprevention. Boca Raton, FL: CRC Press, 1992; 227-245.
162. Hong J-Y, Lin MC, Wang ZY, Wang E-J, Yang CS. Inhibition of chemical toxicity and carcinogenesis by diallyl sulfide and diallyl sulfone. In: Huang M-T, Osawa T, Ho C-T, Rosen TT, eds. Food Phytochemicals for Cancer Prevention I: Fruits and Vegetables. Washington, DC: American Chemical Society, 1994; 97-101.
163. Sugie S, Okumura A, Tanaka T, Mori H. Inhibitory effects of benzyl isothiocyanate and benzyl thiocyanate on diethylnitrosamine-induced hepatocarcinogenesis in rats. Jpn J Cancer Res 84:865-870, 1993.
164. Sugie S, Yoshimi N, Okumura A, Tanaka T, Mori H. Modifying effects of benzyl isothiocyanate and benzyl thiocyanate on DNA synthesis in primary culture of rat hepatocytes. Carcinogenesis 14:281-283, 1993.
165. Wattenberg LW, Loub WD. Inhibition of polycyclic aromatic hydrocarbon-induced neoplasia by naturally occurring indoles. Cancer Res 38:1410-1413, 1978.
166. 1 carcinogen dose, indole-3-carbinol anti-carcinogen dose, target organ DNA adduction and final tumor response. Carcinogenesis 10:175-181, 1989.
167. Morse MA, LaGreca SD, Amin SG, Chung F-L. Effects of indole-3-carbinol on lung tumorigenesis and DNA methylation induced by 4-(methylnitosamino)-1-(3-pyridyl)-1-butanone (NNK), and on the metabolism and disposition of NNK in A/J mice. Cancer Res 50:2613-2617, 1990.
168. Tanaka T, Kojima T, Morishita Y, Mori H. Inhibitory effects of the natural product indole-3-carbinol and sinigrin during initiation and promotion phases of 4-nitroquinoline 1-oxide-induced rat tongue carcinogenesis. Jpn J Cancer Res 83:835-842, 1992.
169. Kojima T, Tanaka T, Mori H. Chemoprevention of spontaneous endometrial cancer in female Donryu rats by dietary indole-3-carbinol. Cancer Res 54:1446-1449, 1994.
170. Bailey GS, Hendricks JD, Shelton DW, Nixon JE, Pawlowski NE. Enhancement of carcinogenesis by the natural anticarcinogen indole-3-carbinol. J Natl Cancer Inst 78:931-934, 1987.
171. Zhang Y, Talalay P, Cho C-G, Posner G. A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc Natl Acad Sci USA 89:2399-2403, 1992.
172. Kensler TW, Egner PA, Dola PM, Groopma JD, Roebuck BD. Mechanism of protection against aflatoxin tumorigenicity in rats fed 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) and related 1,2-dithiol-3-thiones and 1,2-dithiol-3-ones. Cancer Res 47:4271-4277, 1987.
173. Kensler TW, Groopman JD, Roebuck BD. Chemoprevention by oltipraz and other dithiolethiones. In: Wattenberg L, Lipkin M, Boone CW and Kelloff GJ, eds. Cancer Chemoprevention. Boca Raton, FL: CRC Press, 1992; 205-226.
174. Wood AW, Huang M-T, Chang RL, Newmark HL, Lehr RE, Yagi H, Sayer JM, Jerina DM, Conney AH. Inhibition of the mutagenicity of bay-region diol-epoxides of polycyclic aromatic hydrocarbons by naturally occurring plant phenols: exceptional activity of ellagic acid. Proc Natl Acad Sci USA 79:5513-5517, 1982.
175. De Flora S, Astengo M, Serra D, Bennicelli C. Inhibition of urethane-induced lung tumors in mice by dietary N-acetylcysteine. Cancer Lett 32:235-241, 1986.
176. De Flora S, Izzotti A, D'Agostini F, Balansky R, Cesarone CF. Chemopreventive properties of N-acetylcysteine and other thiols. In: Wattenberg L, Lipkin M, Boone CW, Kelloff GJ, eds. Cancer Chemoprevention. Boca Raton, FL: CRC Press, 1992; 183-194.
177. Wattenberg LW, Hochlater B, Galbraith AR. Inhibition of β-propiolactone-induced mutagenesis and neoplasia by sodium thiosulfate. Cancer Res 47:4351-4354, 1987.
178. Tanaka T, Iwata H, Niwa K, Mon Y, Mon H. Inhibitory effect of ellagic acid on N-2-fluorenylacetamide-induced liver carcinogenesis in male ACI/N rats. Jpn J Cancer Res 79:1297-1303, 1988.
179. El-Bayoumy K, Chae Y-H, Upadhyaya P, Meschter C, Cohen LA, Reddy BS. Selenium in chemoprevention of carcinogenesis II. Inhibition of 7,12-dimethylbenz[a]anthracene-induced tumors and DNA adduct formation in the mammary glands of female Sprague-Dawley rats by the synthetic organoselenium compound 1,4-phenylenebis(methylene) selenocyanate. Cancer Res 52:2402-2407, 1992.
180. Reddy BS, Rivenson A, Kulkarni N, Upadhyaya P, El-Bayoumy K. Chemoprevention of colon carcinogenesis by the synthetic organoselenium compound 1,4-phenylenebis(-methylene) selenocyanate. Cancer Res 52:5635-5640, 1992.
181. Steel VE, Stoner GD, Boone CW, Kelloff GJ, eds. Cellular and Molecular Targets for Chemoprevention. Boca Raton, FL: CRC Press, 1992; 1-362.
182. Slaga TJ, Fischer SM, Viaje A, Berry DL, Bracken WM, LeClerc S, Miller DR. Inhibition of tumor promotion by antiinflammatory agents: an approach to the biochemical mechanism of promotion. In: Slaga TJ, Sivak A, Boutwell RK, eds. Mechanisms of Tumor Promotion and Cocarcinogenesis, Vol. 2. New York: Raven Press, 1978; 173-195.
183. Kinzel V, Loehrke H, Goertfler K, Furstenberger G, Marks F. Suppression of the first stage of phorbol 12-tetradecanoate 13-acetate-effected tumor promotion in mouse skin by nontoxic inhibition of DNA synthesis. Proc Natl Acad Sci USA 81:5858-5862, 1984.
184. O'Brien TG, Simsirnan RC, Boutwell RK. Induction of the polyamine-biosynthetic enzymes in mouse epidermis by tumor-promoting agents. Cancer Res 35:1662-1670, 1975.
185. Jänne J, Aihonen L, Leinonen P. Polyamines: from molecular biology to clinical application. Ann Med 23:241-259, 1991.
186. Weeks CE, Herrmann AL, Nelson FR, Slaga TJ. α-Difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits tumor promoter-induced polyamine accumulation and carcinogenesis in mouse skin. Proc Natl Acad Sci USA 79:6028-6032, 1982.
187. Kingsnorth AN, King WWK, Diekema KA, McCann PP, Ross JS, Malt RA. Inhibition of ornithine decarboxylase with 2-difluoromethylornithine: reduced incidence of dimethylhydrazine-induced colon tumors in mice. Cancer Res 43:2545-2549, 1983.
188. Thompson HJ, Herbst EJ, Meeker LD, Monocha R, Ronan AM, Fite R. Effect of concentration of D,L-α-difiuoromethylornithine on murine mammary carcinogenesis. Carcinogenesis 5:1649-1651, 1984.
189. Homma Y, Kakizoe T, Samma S, Oyasu R. Inhibition of N-butyl-N-(4-hydroxybutyl)nitrosamine-induced rat urinary bladder carcinogenesis by α-difluoromethylornithine. Cancer Res 47:4031-4034, 1987.
190. Kingsnorth AN, McCann PP, Diekema KA, Ross JS, Malt RA. Effects of α-difluoromethylornithine on the growth of experimental Wilms' tumors and renal adenocarcinoma. Cancer Res 43:4031-4034, 1983.
191. Tsukahara T, Tamura M, Yamazaki H, Kurihara H, Matsuzaki S. The additive effect of α-difluoromethylornithine (DFMO) and radiation therapy on a rat glioma model. J Cancer Res Clin Oncol 118:171-175, 1992.
192. Tanaka T, Kojima T, Hara A, Sawada H, Mori H. Chemoprevention of oral carcinogenesis by D,L-α-difluoromethylornithine, an ornithine decarboxylase inhibitor: dose-dependent reduction in 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in rats. Cancer Res 53:772-776, 1993.
193. Kojima T, Tanaka T, Kawamori T, Hara A, Mori H. Chemopreventive effects of dietary D,L-α-difluoromethylornithine, an ornithine decarboxylase inhibitor, on initiation and postinitiation stages of diethylnitrosamine-induced rat hepatocarcinogenesis. Cancer Res 53:3905-3907, 1993.
194. Mori H, Tanaka T, Shitna H, Kuniyasu T, Takahashi M. Inhibitory effect of chlorogenic acid on methylazoxymethanol acetate-induced carcinogenesis in large intestine and liver of hamsters. Cancer Lett 30:49-54, 1986.
195. Tanaka T, Kojima T, Kawamori T, Wang A, Suzui M, Okamoto K, Mori H. Inhibition of 4-nitroquinoline 1-oxide-induced rat tongue carcinogenesis by the naturally occurring plant phenolics caffeic, ellagic, chlorogenic and caffeic acids. Carcinogenesis 14:1321-1325, 1993.
196. Tanaka T, Kojima T, Kawamori T, Yoshimi N, Mori H. Chemoprevention of diethylnitrosamine-induced hepatocarcinogenesis by a simple phenolic acid protocatechuic acid in rats. Cancer Res 53:2775-2779, 1993.
197. Tanaka T, Kojima T, Suzui M, Mori H. Chemoprevention of colon carcinogenesis by the natural product of a simple phenolic compound protocatechuic acid: suppressing effects on tumor development and biomarkers expression of colon tumorigenesis. Cancer Res 53:3908-3913, 1993.
198. Hirose Y, Tanaka T, Kawamori T, Ohnishi M, Makita H, Mori H, Satoh K, Hara A. Chemoprevention of urinary bladder carcinogenesis by the natural phenolic compound protocatechuic acid in rats. Carcinogenesis 16:2337-2342, 1995.
199. Tanaka T, Kawamori T, Ohnishi M, Okamoto K, Mori H, Hara A. Chemoprevention of 4-nitroquinoline 1-oxide-induced oral carcinogenesis by dietary protocatechuic acid during initiation and postinitiation phases. Cancer Res 54:2359-2365, 1994.
200. Tanaka T, Kojima T, Kawamori T, Mori H. Chemoprevention of digestive organs carcmogenesis by natural product protocatechuic acid. Cancer (Phila.) 75:1433-1439, 1995.
201. Hocman G. Chemoprevention of cancer: phenolic antioxidants (BHT, BHA). Int J Biochem 20:639-651, 1988.
202. Bird RP, McLellan EA, Bruce WR. Aberrant crypts, putative precancerous lesions, in the study of the role of diet in the aetiology of colon cancer. Cancer Surveys 8:189-200, 1989.
203. Bird RP. Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. Cancer Lett 93:55-71, 1995.
204. Kawamori T, Tanaka T, Kojima T, Suzui M, Ohnishi M, Mori H. Suppression of azoxymethane-induced rat colon aberrant crypt foci by dietary protocatechuic acid. Jpn J Cancer Res 85:686-691, 1994.
205. Kawamori T, Tanaka T, Mori H. Suppression of azoxymethane-induced rat colon aberrant crypt foci by D,L-α-difluoromethylornithine in drinking water (in Japanese). J Jpn Res Soc Gastroenterol Carcinogenesis 7:223-225, 1995.
206. Verma AK, Rice HM, Shapas BG, Boutwell RK. Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced ornithine decarboxylase activity in mouse epidermis by vitamin A analogs (retinoids). Cancer Res 38:793-801, 1978.
207. Mori H, Yoshimi N, Sugie S, Tanaka T, Morishita Y, Jinlong G, Tamai Y, Torihara M, Yamahara J. Inhibitory effect of 5-hydroxy-4-(2-phenyl-(E)-2(SH)-furanone, a novel synthesized retinoid, on azoxymethane-induced intestinal carcinogenesis in rats. Cancer Lett 66:93-98, 1992.
208. Makita H, Tanaka T, Ohnishi M, Tamai Y, Toriliara M, Yamahara J, Mori H, Satoh K, Hara A. Inhibition of 4-nitroquinoline 1-oxide-induced rat oral carcinogenesis by dietary exposure of a new retinoidal butenolide, KYN-54, during the initiation and postinitiation phases. Carcinogenesis 16:2171-2176, 1995.
209. Teelmann K, Tsukaguchi T, Klaus M, Eliason IF. Comparison of the therapeutic effects of a new arotinoid, Ro 40-8757, and all-trras-and 13-cis-retinoic acids on rat breast cancer. Cancer Res 53:2319-2325, 1993.
210. Tanaka T, Makita H, Olinishi M, Mori H, Satoh K, Hara A. Inhibition of oral carcinogenesis by the arotinoid mofarotene (Ro 40-8757) in male F344 rats. Carcinogenesis 16:1903-1907, 1995.
211. Tanaka T, Makita H, Ino N, Rahman W, Mori H, Satoh K, Hara A. Modifying effects of the arotinoid mofarotene (Ro 40-8757) on azoxymethane-induced rat colon and liver carcinogenesis. Cancer J 9:260-268, 1996.
212. Marnett IJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 52:5575-5589, 1992.
213. Zenser TV, Davis BB. Arachidonic acid metabolism. In: Steel VE, Stoner GD, Boone CW, Kelloff GJ, eds. Cellular and Molecular Targets for Chemoprevention. Boca Raton, FL: CRC Press, 1992; 225-245.
214. Reddy BS. Inhibitors of the arachidonic acid cascade and their chemoprevention of colon carcinogenesis. In: Wattenberg L, Lipkin M, Boone CW, Kelloff GJ, eds. Cancer Chemoprevention. Boca Raton, FL: CRC Press, 1992; 153-164.
215. Tanaka T, Nishikawa A, Mori Y, Morishita Y, Mori H. Inhibitory effects of non-steroidal anti-inflammatory drugs, piroxicam and indomethacin on 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in male ACI/N rats. Cancer Lett 48:177-182, 1989.
216. Thun MJ, Namboodiri MM, Calle EE, Dana Flanders W, Heath CWJ. Aspirin use and risk of fatal cancer. Cancer Res 53:1322-1327, 1993.
217. Huang M-T, Lysz T, Ferraro T, Abidi TF, Laskin JD, Conney AH. Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. Cancer Res 51:813-819, 1991.
218. Kato R, Nakadate T, Yamamoto S, Sugimura T. Inhibition of 12-O-tetradecanoylphosbol-13-acetate-induced tumor promotion and ornithine decarboxylase activity by quercetin: possible involvement of lipoxygenase inhibition. Carcinogenesis 4:1301-1305, 1983.
219. Fischer SM, Gleason GL, Hardin LG, Bohrman JS, Slaga TJ. Prostaglandin modulation of phorbol ester skin tumor promotion. Carcinogenesis 1:245-248, 1980.
220. Huang M-T, Smart RC, Wong C-Q, Conney AH. Inhibitory effect of curcumin, chlorogenic acid, caffeic acid, and ferulic acid on tumor promotion in mouse skin by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 48:5941-5946, 1988.
221. Kawamori T, Tanaka T, Hara A, Yamahara J, Mori H. Modifying effects of naturally occurring products on the development of colonic aberrant crypt foci induced by azoxymethane in F344 rats. Cancer Res 55:1277-1282, 1995.
222. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, Dubois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107:1183-1188, 1994.
223. Boolbol SK, Dannenberg AJ, Chadburn A, Martucci C, Guo X-J, Ramonetti JT, Abreu-Goris M, Newmark HL, Lipkin ML, DeCosse JJ, Bertagnolli MM. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 56:2556-2560, 1996.
224. Reddy BS, Rao CV, Seibert K. Cancer Res 56:4566-4569, 1996.
225. Slaga TJ, Klein-Szanto AJP, Triplett LL, Yotti LP, Trosko JE. Skin tumor-promoting activity of benzoyl peroxide, a widely used free radical-generating compound. Science 213:1023-1025, 1981.
226. Troll W, Kiassen A, Janoff A. Tumorigenesis in mouse skin: inhibition by synthetic inhibitors of proteases. Science 169:1211-1213, 1970.
227. Troll W, Frenkel K, Wiesner R. Protease inhibitors as anticarcinogens. J Natl Cancer Inst 73:1245-1250, 1984.
228. Troll W, Wiesner R, Frenkel K. Anticarcinogenic action of protease inhibitors. Adv Cancer Res 49:265-283, 1987.
229. Hocman G. Chemoprevention of cancer: protease inhibitors. Int J Biochem 24:1365-1375, 1992.
230. Troll W, Lim JS, Belman S. Protease inhibitors suppress carcinogenesis in vivo and in vitro. In: Wattenberg L, Upkin M, Boone CW, Kelloff GJ, eds. Cancer chemoprevention. Boca Raton, FL: CRC Press, 1992; 503-512.
231. Redwood SM, Liu BC, Weiss RE, Hodge DE, Droller MJ. Abrogation of the invasion of human bladder tumor cells by using protease inhibitor(s). Cancer 69:1212 1219, 1992.
232. Moon RC, Rao KVN, Detrisac CJ, Kelloff GJ. Retinoid chemoprevention of lung cancer. In: Wattenberg L, Upkin M, Boone CW, Kelloff GJ, eds. Cancer Chemoprevention. Boca Raton, FL: CRC Press, 1992; 83-93.
233. Kotan R. Evaluation of clinical trials with retinoids in relation to their basic mechanism of action. In: Wattenberg L, Lipkin M, Boone CW, Kelloff GJ, eds. Cancer Chemoprevention. Boca Raton, FL: CRC Press, 1992; 71-82.
234. Hossain MZ, Wilkens LR, Mehta PP, Lowenstein W, Bertram JS. Enhancement of gap junctional communication by retinoids correlated with their ability to inhibit neoplastic transformation. Carcinogenesis 10:1743-1748, 1989.
235. Teelmann K. Retinoids: toxicity and teratogenicity to date. Pharmacol Ther 40:29-43, 1989.
236. Tanaka T, Morishita Y, Suzui M, Kojima T, Okumura A, Mori H. Chemoprevention of mouse urinary bladder carcinogenesis by the naturally occurring carotenoid astaxanthin. Carcinogenesis 1994: 15-19, 1994.
237. Tanaka T, Makita H, Ohnishi M, Mori H, Satoh K, Hara A. Chemoprevention of rat oral carcinogenesis by naturally occurring xanthophylls, astaxanthin and canthaxanthin. Cancer Res 55:4059-4064, 1995.
238. Tanaka T, Kawamori T, Olinishi M, Makita H, Mori H, Satoh K, Hara A. Suppression of azoxymethane-induced rat colon carcinogenesis by dietary administration of naturally occurring xanthophylls astaxanthin and canthaxanthin during the postinitiation phase. Carcinogenesis (Lond.) 16:2957-2963, 1995.
239. Pence BC. Calcium and vitamin D effects on tumor promotion in the colon and mouse skin. In: Lipkin M, Newmark HL, Kelloff GJ, eds. Cancer Chemoprevention. Boca Raton, FL: CRC Press, 1991; 191-206.
240. Carroll KK, Eckel LA, Fraher LJ, Frei JV, Newniark HL. Dietary calcium, phosphate, and vitamin D in relation to mammary carcinogenesis. In: Lipkin M, Newmark HL, Kelloff GJ, eds. Calcium, Vitamin D, and Prevention of Colon Cancer. Boca Raton, FL: CRC Press, 1991; 229-236.
241. Tanaka T, Shinoda T, Yoshimi N, Niwa k, Iwata H, Mori H. Inhibitory effect of magnesium hydroxide on methylazoxymethanol acetate-induced large bowel carcinogenesis in male F344 rats. Carcinogenesis 10:613-616, 1989.
242. Mori H, Morishita Y, Mori Y, Yoshimi N, Sugie S, Tanaka T. Effect of magnesium hydroxide on methylazoxymethanol acetate-induced epithelial proliferation in the large bowels of rats. Cancer Lett 62:43-48, 1992.
243. Frenkel K. Carcinogen-induced oxidant formation and oxidative DNA damage. Pharmacol Ther 53:127-166, 1992.
244. Santamaria I, Bianchi-Santamria A. Free radicals as carcinogens and their quenchers as anticarcinogens. Med Oncol Tumor Pharmacother 8:121-140, 1991.
245. Wei H, Frenkel K. Suppression of tumor-promoter-induced oxidative events and DNA damage in vivo by sarcophytol A: possible mechanism of antipromotion. Cancer Res 52:2298-2303, 1992.
246. Fujiki H, Suganuma M, Suguri H, Yoshizawa S, Takagi K, Kobayashi M. Sarcophytols A and B inhibit tumor promotion by teleocidin in two-stage carcinogenesis in mouse skin. J Cancer Res Clin Oncol 115:25-28, 1989.
247. O'Connel JF, Klein-Szanto AJP, DiGiovanni DM, Fries JW, Slaga TJ. Enhanced malignant progression of mouse skin tumors by the free-radical generator benzoyl peroxide. Cancer Res 46:2863-2865, 1986.
248. Rotstein JB, Slaga TJ. The enhanced progression of papilloma by peroxides in the 2-stage mouse model. Proc Am Assoc Cancer Res 27:143, 1986.
249. Rotstein JB, Slaga TJ. Effect of exogenous glutathione on tumor progression in the murine skin multistage carcinogenesis model. Carcinogenesis 9:1547-1551, 1988.
250. Malone WF. Chemoprevention research. In: Weisburger EK, ed. Mechanisms of Carcinogenesis. Cancer Growth and Progression, Vol.2. Dordrecht: Kluwer Academic Press, 1989; 31-42.
251. Bertram JS, Kolonel LN, Meyskens FL. Rationale and strategies for chemoprevention of cancer in humans. Cancer Res 47:3012-3031, 1987.
252. Greenwald P. NCI cancer prevention and control research. Prev Med 22:642-660, 1993.
253. Greenwald P, Sondik E. Diet and chemoprevention in NCI's research strategy to achieve national cancer control objectives. Ann Rev Public Health 7:267-291, 1986.
254. Meyskens FLJ. Thinking about cancer causality and chemotherapy. J Natl Cancer Inst 80:1278-1281, 1988.
255. Friend SH, Dryja TP, Weinberg RA. Oncogenes and tumor-suppressor genes. N Engl J Med 318:618-622, 1988.
256. Taylor JA. Oncogenes and their applications in epidemiologic studies. Am J Epidemiol 130:6-13, 1989.
257. Sporn MB, Roberts AB. Transforming growth factor-α. Multiple actions and potential clinical applications. JAMA 262:938-941, 1989.
258. Munger K, Pietenpol JA, Pittelkow MR, Holt IT, Moses HL. Transforming growth factor β1 regulation of c-myc expression, pRB phosphorylation and cell cycle progression in keratinocytes. Cell Growth Different 3:291-298, 1992.
259. Miyamoto H, Kubota Y, Shin T, Torigoe S, Dobashi Y, Hosaka M. Expression of transforming growth factor-β1 in human bladder cancer. Cancer 75:2565-2570, 1995.
260. Hsu S, Huang F, Hafez M, Winawer S, Friedman E. Colon carcinoma cells switch their response to transforming growth factor-β1 with tumor progression. Cell Growth Different. 5:267-275, 1994.
261. Kelloff GJ, Boone CW, Malone WF, Steel VE. Chemoprevention clinical trials. Mutat Res 267:291-295, 1992.
262. Goodman GE. The clinical evaluation of cancer chemoprevention agents: defining and contrasting Phase I. II. and III objectives. Cancer Res 52 (Suppl):2752s 2757s, 1992.
263. Lippman SM, Benner SE, Hong WK. Cancer chemoprevention. J Clin Oncol 12:851-873, 1994.
264. Alberts DS. Forewords: Fourth International Conference on Prevention of Human Cancer: Nutrition and Chemoprevention Controversies, Tucson, Arizona, June 3-6, 1992. Prev Med 22:629-641, 1993.
265. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, Schantz SP, Kramer AM, Lotan R, Peters LJ, Dimery IW, Brown BW, Goepfert H. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 3232:795-801, 1990.
266. Love RR, Carbone PP, Verma AK, Gilmore D, Carey P, Tutsch KD, Pomplun M, Wilding G. Randomized Phase I chemoprevention study of α-difluoromethylornithine. J Natl Cancer Inst 85:732-737, 1993.
267. Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 85:1220-1224, 1993.
268. de Vries N, van Zandwijk N, Pastorino U, on behalf of the EUROSCAN Steering Coniinittee. The Euroscan study. Br J Cancer 64:985-989, 1991.
269. Benner SE, Winn RJ, Lippman SM, Poland J, Hansen KS, Luna MA, Hong WK. Regression of oral leukoplakia with α-tocopherol: a community clinical oncology program chemoprevention study. J Natl Cancer Inst 85:44-47, 1993.
270. The Alpha-Tocopherol, beta Carotene Cancer Prevention Study Group. The Effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330:1029-1035, 1994.
271. McLarty JW, Holiday DB, Girard WM, Yanagihara RH, Kumment TD, Greenberg SD. β-Carotene, vitamin A, and lung cancer chemoprevention: results of an intermediate end-point study. Am J Clin Nutr 62 (suppl):1431s-1438s, 1995.
272. Albanes D, Heinonen OP, Huttunen JK, Taylor PR, Virtamo J, Edwards BK, Haapakoski J, Rautalahti M, Hartman AM, Palmgren J, Greenwald P. Effects of α-tocopherol and β-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study. Am J Clin Nutr 62 (suppl):1427s-1430s, 1996.
273. Omenn GS, Goodman G, Thornquist M, Grizzle J, Rosenstock L, Barnhart S, Balmes J, Cherniack MG, Cullen MR, Glass A, Keogh J, Meyskens FJ, Valanis B, Williams JJ. The β-carotene and retinol efficacy trial (CARET) for chemoprevention of lung cancer in high risk populations: smokers and asbestos-exposed workers. Cancer Res 54 (Suppl):2038s-2043s, 1994.
274. Shima H, Kuniyasu T, Sugie S, Tanaka T, Mori H, Takahashi M, Muto Y. Inhibitory effects of polyprenoic acid (F-S 166) on N-2-fluorenylacetamide-induced hepatocarcinogenesis in rats. Jpn J Cancer Res 77:351-355, 1985.
275. Fukutomi Y, Omori M, Muto Y, Ninomiya M, Okuno M, Moriwaki H. Inhibitory effects of acyclic retinoid (polyprenoic acid) and its hydroxy derivative on cell growth and on secretion of alpha-fetoprotein in human hepatoma-derived cell line (PLC/ PRF/5). Jpn J Cancer Res 81:1281-1285, 1990.
276. Nakamura N, Shidoji Y, Yamada Y, Hatakenaka H, Moriwaki H, Muto Y. Induction of apoptosis by acyclic retinoid in the human hepatoma-derived cell line, HuH-7. Biochem Biophys Res Commun 207:382-388, 1995.
277. Yamada Y, Shidoji Y, Fukutomi Y, Ishikawa T, Kaneko T, Nakagawa H, Imawari M, Moriwaki H, Muto Y. Positive and negative regulations of albumin gene expression by retinoids in human hepatoma cell lines. Mol Carcinogenesis 10:151-158, 1994.
278. Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki T, Tanaka T, Tsurumi K, Okuno M, Tomita E, Nakamura T, Kojima T. Prevention of second primary tumors by a retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 334:1561-1567, 1996.
279. Henderson BE, Ross RK, Pike MC. Hormonal chemoprevention of cancer in women. Science 259:633-635, 1993.
280. Kelloff GI, Boone CV, Crowell IA, Nayfield SG, Hawk F, Steele VE, Lobet RA, Sigman CC. J cell Biochem. Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary. J Cell Biochem 23 (Suppl):1-9, 1995.
281. Barnes S, Peterson TG, Coward L. Rationale for the use of genistein-containing soy matrices in chemoprevention trials for breast and prostate cancer. J Cell Biochem 22 (Suppl):181-187, 1995.
282. Feigl P, Blumenstein B, Thompson L, Crowley J, Wolf M. Kramer BS, Coltman CA Jr, Brawley OW, Ford LG. Design of the prostate cancer prevention trial (PCPT). Contr Clin Trials 16:150-163, 1995.
283. Kelloff GI, Boone CW, Malone WF, Steele VE, Doody LA. Development of chemopreventive agents for bladder cancer. J Cell Biochem 161:1-12, 1992.
284. Hennekens CH, Buring JE, Menson JF, Stampfer M, Rosner B, Cook NR, Belanger C, LaMotte F, Gaziano JM, Ridker PM, Willett W, Peto R. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J 334:1145-1149, 1996.
285. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL Jr, Valanis BV, Williams JH Jr, Barnhart S, Hammar S. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334:1150-1155, 1996.
286. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh P, Meskens FL Jr, Valanis BV, Williams JH Jr, Barnhart S, Cherniack MG, Brodkin CA, Hammar S. Risk factors for lung cancer and for intervention effects in CARET, the beta-carotene and retinol efficacy trial. J Natl Cancer Inst 88:1550-1559, 1996.
287. Albanes D, Heinonen OP, Taylor PR, Virtamo I, Edwards BK, Rautalahti M, Hartman AM, Palmgren I, Freedman LS, Haapakoski J, Barrett MJ, Pietinen P, Malila N, Tala E, Liippo K, Salomaa F-R, Tangrea JA, Teppo, L, Askin FB, Taskinen E, Erozan Y, Greenwald P, Huttunen JK. α-Tocopherol and β-carotene supplements and lung cancer incidence in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study: Effects of base-line characteristics and study conipliance. J Natl cancer Inst 88:1560-1570, 1996.
288. Mayne ST, Handelman GI, Beecher G. β-Carotene and lung cancer promotion in heavy smoker-a plausible relationship? J Natl Cancer Inst 88:1513-1515, 1996.
289. Hong WK, Fndicott J, Itri LM, Doos W, Batsakis JG, Bell R, Fofonoff S, Byers R, Atkinson EN, Vaughan C, Toth BB, Kramer A, Dimery IW, Skipper P, Strong S. 13-cis-Retinoic acid in the treatment of oral leukoplakia. N Engl J Med 315:1501-1505, 1986.
290. Dimery I, Shirinian M, Heyne K. Reduction in toxicity of high dose 13-cis-retinoic acid (13-cRA) with α-tocopherol (AT). Proc ASCO 11:399, 1992.
291. Bolla M, Lefur R, Ton Van J, Domenge C, Badet JM, Koskas Y, Laplanche A. Prevention of second primary tumours with etretinate in squamous cell carcinoma of the oral and oropharynx. Results of a multicentric double-blind randomised study. Eur J Cancer 30A:767-772, 1994.
292. Upkin M. Biomarkers of increased susceptibility to gastrointestinal cancer: New application to studies of cancer prevention in human subjects. Cancer Res 48:235-245, 1988.
293. Lippman SM, Lee JS, Lotan R, Hittelman W, Wargovich MJ, Hong WK. Biomarkers as intermediate end points in chemoprevention trials. J Nafi Cancer Inst 82:555-560, 1990.
294. Zelen M. Are primary cancer prevention trials feasible? J Natl Cancer Inst 80:1442-1444, 1988.
295. Virji M, Mercer DW, Herberman RB. Tumor markers in cancer diagnosis and prognosis. Cancer J Clin 38:104-126, 1988.
296. Greenwald P, Witkin KM, Malone WF, Byar DP, Freedman LS, Stern HR. The study of markers of biological effect in cancer prevention research trials. Int J Cancer 52:189-196, 1992.
297. Lippman SM, Hitteima WN. Recent advances in cancer chemoprevention. Cancer Cells 3:59-65, 1991.
298. Lee JS, Lippman SM, Hong WK, Ro JY, Kim SY, Lotan R, Hittelman WN. Determination of biomarkers for intermediate end points in chemoprevention trials. Cancer Res 52:2707-2710, 1992.
299. Upkin M, Levin B, Kini YS, Kelloff GJ, eds. Intermediate Biomarkers of Precancer and Their Application in Chemoprevention. J Cell Biochem, Vol. 16G (Suppl). New York: Wiley-Liss, 1992; 1-196.
300. Scalmati A, Lipkin M. Proliferation and differentiation biomarkers in colorectal mucosa and their application to chemoprevention studies. Environ Health Perspect 99:169-173, 1993.
301. Hemstreet GP III, Rao JY, Hurrst RE, Bonner RB, Jones PL, Vaidya AM, Fradet Y, Moon RC, Kelloff GJ. Intermediate endpoint biomarkers for chemoprevention. J Cell Biochem 161 (Suppl):93-110, 1992.
302. Thompson TC, Truong LD, Timme TL, Kadmon D, McCune BK, Flanders KC, Scardino PT, Park SH. Transforming growth factor bi as a biomarker for prostate cancer. J Cell Biochem 16H (Suppl):54-61, 1992.
303. Greenwald P, Nixon DW, Malone WF, Kelloff GJ, Stern HR, Witkin KM. Concepts in cancer chemoprevention research. Cancer 65:1483-1490, 1990.
304. Thiele CJ, Reynolds CP, Israel MA. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human retinoblastoma. Nature 313:404-406, 1985.
305. Sporn MB, Roberts AB. Role of retinoids in differentiation and carcinogenesis. Cancer Res 43:3034-3040, 1983.
306. O'Brian CA, Liskamp RM, Solomon DH, Weinstein IB. Triphenylethylenes: a new class of protein kinase C inhibitors. J Natl Cancer Inst 76:1243-1246, 1986.
307. Powles TJ. The case for clinical trials of tamoxifen for prevention of breast cancer. Lancet 340:1145-1147, 1992.
308. Hirsimaki P, Hirsimaki Y, Nieminen I, Payne BJ. Tamoxifen induces hepatocellular carcinoma in rat liver: a one year study with two antiestrogens. Arch Toxicol 67:49-54, 1993.
309. Williams GM, latropoulos MJ, Djordjevic MV, Kaltenberg OP. The triphenylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 14:315-317, 1993.
310. Greaves P, Goonetilleke R, Nunn G, Topham J, Orton T. Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 53:3919-3924, 1993.
311. Rutqvist LE, Johansson H, Signomklao T, Johnansson U, Fornader T, Wuilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primart maliagnancies. J Natl Cancer Inst 87:645-650, 1995.
312. IARC. Monograph conclusion on tamoxifen. Lancet 347:605, 1996.
313. Martin EA, Carthew P, White INH, Smith LL. A lifetime feeding study of tamoxifen in three strains of mice. The Toxicologist 30:201, 1996.
314. Carthew P, Edwards RE, Nolan BM, Martin EA, Smith LL. Tamoxifen associated uterine pathology in rodents: relevance to women. Carcinogenesis 17:1577-1582, 1996.
315. Rutqvist LE, Hatschek T, Rydén S, Bergh J, Bengtsson N-O, Carstenssen J, Nordenskjöld B, Wallgren A (Breast Cancer Cooperative Group). Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 88:1543-1549, 1996.
316. Fisher B, Dignam I, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino I, Redmond C, Fisher ER, Bowman DM, Deschênes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz I, Paterson AHG, Feldman MI, Farrar W, Evans J, Lickey HL. Five versus more than five years of tamoxifen therapy {or breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88:1529-1542, 1996.
317. Drebin JA, Link VC, Stern DF, Weinberg RA, Greene MI. Down modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41:697-706, 1985.
318. Castagna M, Takai Y, Kaibuchi K, Sano K, Kikkawa U, Nishizuka Y. Direct activation of calcium-activated phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem 257:7847-7851, 1982.
319. Fujiki H, Suganuma M, Takagi K, Nishiwaki S, Yoshizawa S, Okabe S, Yatsunami J, Frenkel K, Troll W, Marshall JA, Tius MA. Sarcophytol A and its analogs: cancer prevention activity. In: Huang M-T, Ho C-T, Lee CY, eds. Phenolic Compounds in Food and Their Effects on Health II. Washington, DC: American Chemical Society, 1992; 380-387.
320. Komori A, Yatsunami J, Suganuma M, Okabe S, Abe S, Sakai A, Sasaki K, Fujiki H. Tumor necrosis factor acts as a tumor promoter in BALB/3T3 cell transformation. Cancer Res 53:1982-1985, 1993.
321. Komori A, Suganuma M, Okabe S, Okabe S, Zou X, Tius MA, Fujiki H. Canventol inhibits tumor promotion in CD-1 mouse skin through inhibition of tumor necrosis factor a release and of protein isoprenylation. Cancer Res 53:3462-3464, 1993.
322. Crowell PL, Chang RR, Ren Z, Elson CE, Gould MN. Selective inhibition of isoprenylation of 21-26-kDa proteins by the anticarcinogen d-limonene and its metabolites. J Biol Chem 266:17679-17685, 1991.
323. Barbacid M. Ras genes. Annu Rev Biochem 56:779-827, 1987.
324. Feig LA. Strategies for suppressing the function of oncogenic ras protein in tumors. J Natl Cancer Inst 85:1266-1268, 1993.
325. Hancock JF, Magee AI, Childs JF, Marshall CJ. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 57:1167-1177, 1989.
326. Gibbs JB. Ras c-terminal processing enzymes: new drug target? Cell 65:1-4, 1991.
327. Frebourg T, Friend SH. The importance of p53 gene alterations in human cancer: Is there more than circumstantial evidence? J Natl Cancer Inst 85:1554-1557, 1993.
328. Weinstein RA. The action of oncogene in the cytoplasm and nucleus. Science 230:770-776, 1985.
329. Lyons RM, Moses HL. Transforming growth factors and the regulation of cell proliferation. Fur J Biochem 187:467-473, 1990.
330. Wyke JA. Matching basic research to the management of cancer: the view from the other side of the fence. Br J Cancer 62:341-347, 1990.
331. Huang M, Ye Y, Chen S, Chai J, Lu J-X, Lin Z, Gu L, Wang Z. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567-572, 1988.
332. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, Degos L. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 76:1704-1709, 1990.
333. Warrell RP, Fankel SR, Miller WH, Scheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreeff M, Tafuri A, Jakubowski A, Gabrilove J, Gordon MS, Dmitrovsky F. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid). N Engl J Med 324:1385-1393, 1991.
334. Sachs L. The control of growth and differentiation in norinal and leukemic blood cells. Cancer 67:2684-2694, 1991.
335. Weisburger JH, Griswold DP, Prejean JD, Casey AF, Wood HB, Weisburger EK. The carcinogenic properties of some of the principal drugs used in clinical cancer chemotherapy. Recent Results Cancer Res 52:1-17, 1975.
336. IARC. Some anticarcinogenic and immunosuppressive agents. In: IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, Vol. 26. Lyon: IARC, 1981.
337. Rosenberg SA. Immunotherapy and gene therapy of cancer. Cancer Res 51 (Suppl):5074s-5079s, 1991.
338. Foa R, Guarini A, Gansbacher B. 1L2 treatment for cancer: from biology to gene therapy. Br J Cancer 66:992-998, 1992.
339. Gutierrez AA, Lemoine NR, Sikora K. Gene therapy for cancer. Lancet 339:715-721, 1992.
340. Carter G, Lemoine NR. Antisense technology for cancer therapy: does it make sense? Br J Cancer 67:869-876, 1993.
341. Rosenberg SA. The immunotherapy and gene therapy of cancer. J Clin Oncol 10:180-188, 1992.
342. Herlyn M, Menrad A, Koprowski H. Structure, function, clinical significance of human tumor antigen. J Natl Cancer Inst 82:1883-1889, 1990.
343. Napolitano LA, Vogel J, Jay G. The role of major histocompatibility complex class I antigens in tumorigenesis: future applications in cancer therapy. Biochim Biophys Acta 989:153-162, 1989.
344. Weinstein IB. Strategies for inhibiting multistage carcmogenesis based on signal transduction pathways. Mutat Res 202:413-420, 1988.
345. Woll PJ. Neuropeptide growth factors and cancer. Br J Cancer 63:469-475, 1991.
346. Grunicke HH. The cell membrane as a target for cancer chemotherapy. Fur J Cancer 27:281-284, 1991.
347. Folkinan J, Ingber D. Inhibition of angiogenesis. Cancer Biol 3:89-96, 1992.
348. Holder JW, Elmore F, Barrett JC. Gap junction function and cancer. Cancer Res 53:3475-3485, 1993.
349. Kohl NE, Mosser SD, deSolms SJ, Giuliani EA, Pompliano DL, Graham SL, Smith RL, Scolnick EM, Oliff A, Gibbs JB. Selective inhibition of ras-dependent transformation by a famesyltransferase inhibitor. Science 260:1934-1937, 1993.
350. James GL, Goldsteinm JL, Brown MS, Rawson TE, Somers TC, McDowell RS, Crowley CW, Lucas BK, Levinson AD, Marsters JCJ. Benzodiazepine peptidomimetics: potent inhibitors of ras farnesylation in animal cells. Science 260:1937-1942, 1993.
351. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, Shibuya M, Fukami Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 262:5592-5595, 1987.
352. Hunter T, Cooper JA. Protein-tyrosine kinase. Annu Rev Biochem 54:897-930, 1985.
353. Wei H, Wei L, Fenkel K, Bowen R, Barnes S. Inhibition of tumor promoter-induced hydrogen peroxide formation in vitro and in vivo by genistein. Nutr Cancer 20:1-12, 1993.
354. Barnes S, Grubbs C, Setchell KDR, Carlson J. Soybeans inhibit mammary tumors in models of breast cancer. In: Pariza M, Liss AR, eds. Mutagens and Carcinogens in the Diet. New York: Wiley-Liss, 1990; 239-253.
355. Okura A, Arakawa H, Oka h, Yoshinari T, Monden Y. Effect of genistein on topoisomerase activity and on the growth of [Vall2]Ha-ras-transformed NIH 3T3 cells. Biochem Biophys Res Commun 157:183-189, 1988.
356. Zwiller J, Sassone-Corsi P, Kakazu K, Boyton AL. Inhibition of PDGF-induced c-jun and c-fos expression by a tyrosine protein kinase inhibitor. Oncogene 6:219-221, 1991.
357. Yamashita Y, Kawada S, Nakano H. Induction of mammalian topoisomerase II dependent DNA cleavage by nonintercalative flavonoids, genistein and orobol. Biochem Pharmacol 39:737-744, 1990.
358. Linassier C, Pierre M, Le Peco J-B, Pierre J. mechanisms of action in NIH 3T3 cells of genistein, and inhibitor of EGF receptor tyrosine kinase activity. Biochem Pharmacol 39:187-193, 1990.
359. Gyorgy P, Murata K, Ikehata H. Antioxidants isolated from fermented soybeans (Tempeh). Nature 203:870-872, 1964.
360. Huang M-T, Wood AW, Newmark HL, Sayer JM, Yagi H, Jerina DM, Conney AH. Inhibition of the mutagenicity of bay-region diol-epoxides of polycyclic aromatic hydrocarbons by phenolic plant flavonoids. Carcinogenesis 4:1631-1637, 1983.
361. Blumberg PM. Protein kinase C as the receptor for the phorbol ester tumor promoters. Cancer Res 48:1-8, 1988.
362. O'Brian CA, Ward NE, bannides CG, Dong Z. Potential strategies of chemoprevention through modulation of protein kinase C activity. In: Steel VE, Stoner GD, Boone CW, Kelloff GJ, eds. Cellular and Molecular Targets for Chemoprevention. Boca Raton, FL: CRC Press, 1992; 161-172.
363. Nakadate T, Jeng AY, Blumberg PM. Comparison of protein kinase C functional assays to clarify mechanisms of inhibitor action. Biochem Pharmacol 37:1541-1545, 1988.
364. Schwarz GK, Jiang J, Kelsen D, Albino AP. Protein kinase C: a novel target for inhibiting gastric cancer cell invasion. J Natl Cancer Inst 85:402-407, 1993.
365. Crooke St, Mirabelli CK. Application of oligonucleotide drugs for cancer prevention. In: Steel VE, Stoner GD, Boone CW, Kelloff GJ, eds. Cellular and Molecular Targets for Chemoprevention. Boca Raton, FL: CRC Press, 1992; 83-92.
366. Boutorine AS, Boiziau C, LeDoan T, Toulme JJ, Helene C. Effect of the terminal phosphate derivatization of beta-and alpha-oligonucleotides on their antisense activity in protein biosynthesis, stability and uptake by eukaryotic cells. Biochemie 74:485-489, 1992.
367. Tanaka T, Makita H, Ohnishi M, Hirose Y, Wang A, Mori H, Satoh K, Hara A, Ogawa H. Chemoprevention of 4-nitroquinoline 1-oxide-induced oral carcinogenesis by dietary curcumin and hesperidin: comparison with the protective effect of β-carotene. Cancer Res 54:4653-4659, 1994.
368. Jiang WG. E-cadherin and its associated protein, cancer invasion and metastasis. Br J Surg 83:437-446, 1996.
369. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370:61-65 1994.
370. Seiki M. Membrane types-matrix metalloproteinase and tumor invasion. Curr Topics Microbiol Immunol 213(Pt 1):23-32, 1996.
371. Honn KV, Cicone B, Skoff A: Prostacyclin, a potent antimetastatic agent. Science 212:1270-1272, 1981.
372. Honn KV, Tang DG, Gao X, Butovich IA, Liu B, Timar J, Hagmann W. 12-Lipoxygenase and 12(S)-HETE: role in cancer metastasis. Cancer Metastasis Rev. 13:365-396, 1994.
373. Fazioli F, Blasi F. Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy? Trends Pharmacol Sci 15:25-29, 1994.
374. Morla A, Zhang Z, Ruoslahti. Superfibronectin is a functionally distinct from fibronectin. Nature 367:193-196, 1994.
375. Pasqualini R, Bourdoulous S, Koivunen E, Woods VL, Rouslahti E. A polymeric form of fibronectin has antirnetastatic effects against multiple tumor types. Nature Med. 2:1197-1203, 1996.
376. Kundu N, Beaty TL, Jackson MJ, Fulton AM. Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer. J Natl Cancer Inst 88:536-541, 1996.
377. Nicolson GL. Bioregulators come of age in the control of tumor growth and metastasis. Natl Cancer Inst 88:479-480, 1996.